It found patients given low-dose theophylline add-on therapy or the leukotrine receptor antagonist montelukast for asthma had lower cardiovascular disease blood risk factors.
Both drugs are recommended by British Thoracic Society/SIGN guidelines for asthma patients who do not respond to long acting beta-2 agonists.
The study included 489 patients aged from 15-79 years who were diagnosed with asthma, but had an FEV1 greater than 50 per cent.
Dr Steve Holmes, Somerset GP and General Practice Airways Group (GPIAG) chairman said: 'This study looked very much at surrogate markers rather than actual outcomes.'
Comment below and tell us what you think
